Cargando…
Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
Somatic CALR mutations occur in approximately 70% of patients with JAK2 V617F-negative essential thrombocythemia (ET) and primary myelofibrosis (PMF). We evaluated the effects of the CALR mutant type and burden on the phenotype of CALR-mutated myeloproliferative neoplasms (MPN). Of the 510 patients...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689478/ https://www.ncbi.nlm.nih.gov/pubmed/36359414 http://dx.doi.org/10.3390/diagnostics12112570 |
_version_ | 1784836545010728960 |
---|---|
author | Kim, Hyun-Young Han, Yujin Jang, Jun Ho Jung, Chul Won Kim, Sun-Hee Kim, Hee-Jin |
author_facet | Kim, Hyun-Young Han, Yujin Jang, Jun Ho Jung, Chul Won Kim, Sun-Hee Kim, Hee-Jin |
author_sort | Kim, Hyun-Young |
collection | PubMed |
description | Somatic CALR mutations occur in approximately 70% of patients with JAK2 V617F-negative essential thrombocythemia (ET) and primary myelofibrosis (PMF). We evaluated the effects of the CALR mutant type and burden on the phenotype of CALR-mutated myeloproliferative neoplasms (MPN). Of the 510 patients with suspected or diagnosed MPN, all 49 patients detected with CALR mutations were diagnosed with ET (n = 32) or PMF (n = 17). The CALR mutant burden was significantly higher in PMF than in ET (45% vs. 34%), and type 1-like and type 2-like mutations were detected in 49% and 51% patients, respectively. Patients with MPN and type 2-like mutation showed a significantly higher median platelet count than those with type 1-like mutation. Particularly, patients with ET and type 2-like mutation had no thrombotic events, despite higher platelet counts. The effect of CALR mutant burden differed depending on the mutant type. A higher mutant burden tended to be associated with a cytopenic phenotype (i.e., lower hemoglobin levels and platelet counts) in patients with the type 1-like mutation and a proliferative hematological phenotype (i.e., higher platelet and neutrophil counts) in patients with the type 2-like mutation. This study suggests that the disease phenotype of MPN may be altered through CALR mutant burden and mutant type. |
format | Online Article Text |
id | pubmed-9689478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96894782022-11-25 Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms Kim, Hyun-Young Han, Yujin Jang, Jun Ho Jung, Chul Won Kim, Sun-Hee Kim, Hee-Jin Diagnostics (Basel) Article Somatic CALR mutations occur in approximately 70% of patients with JAK2 V617F-negative essential thrombocythemia (ET) and primary myelofibrosis (PMF). We evaluated the effects of the CALR mutant type and burden on the phenotype of CALR-mutated myeloproliferative neoplasms (MPN). Of the 510 patients with suspected or diagnosed MPN, all 49 patients detected with CALR mutations were diagnosed with ET (n = 32) or PMF (n = 17). The CALR mutant burden was significantly higher in PMF than in ET (45% vs. 34%), and type 1-like and type 2-like mutations were detected in 49% and 51% patients, respectively. Patients with MPN and type 2-like mutation showed a significantly higher median platelet count than those with type 1-like mutation. Particularly, patients with ET and type 2-like mutation had no thrombotic events, despite higher platelet counts. The effect of CALR mutant burden differed depending on the mutant type. A higher mutant burden tended to be associated with a cytopenic phenotype (i.e., lower hemoglobin levels and platelet counts) in patients with the type 1-like mutation and a proliferative hematological phenotype (i.e., higher platelet and neutrophil counts) in patients with the type 2-like mutation. This study suggests that the disease phenotype of MPN may be altered through CALR mutant burden and mutant type. MDPI 2022-10-23 /pmc/articles/PMC9689478/ /pubmed/36359414 http://dx.doi.org/10.3390/diagnostics12112570 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Hyun-Young Han, Yujin Jang, Jun Ho Jung, Chul Won Kim, Sun-Hee Kim, Hee-Jin Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms |
title | Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms |
title_full | Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms |
title_fullStr | Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms |
title_full_unstemmed | Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms |
title_short | Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms |
title_sort | effects of calr-mutant type and burden on the phenotype of myeloproliferative neoplasms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689478/ https://www.ncbi.nlm.nih.gov/pubmed/36359414 http://dx.doi.org/10.3390/diagnostics12112570 |
work_keys_str_mv | AT kimhyunyoung effectsofcalrmutanttypeandburdenonthephenotypeofmyeloproliferativeneoplasms AT hanyujin effectsofcalrmutanttypeandburdenonthephenotypeofmyeloproliferativeneoplasms AT jangjunho effectsofcalrmutanttypeandburdenonthephenotypeofmyeloproliferativeneoplasms AT jungchulwon effectsofcalrmutanttypeandburdenonthephenotypeofmyeloproliferativeneoplasms AT kimsunhee effectsofcalrmutanttypeandburdenonthephenotypeofmyeloproliferativeneoplasms AT kimheejin effectsofcalrmutanttypeandburdenonthephenotypeofmyeloproliferativeneoplasms |